Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

 
• By Joseph Haas, Jo Shorthouse, Alexandra Shimmings, Jung Won Shin, and Kevin Grogan

AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.

DealWatch_1200x675

More from Deals

More from Business